| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
This compound does not target specific biological receptors but functions through its chelating activity, forming stable water-soluble complexes with various metal ions. As a chelating agent, it efficiently binds polyvalent metal ions including Zn²⁺, Ca²²⁺, Cu²⁺, and Fe³⁺. By sequestering metal ions, it prevents their participation in other reactions or biological processes, thereby indirectly affecting metal-dependent enzymatic reactions and cell signaling pathways.
|
|---|---|
| ln Vitro |
In cell-free systems, disodium nitrilotriacetate exhibits potent metal-chelating capability, forming stable complexes with metal ions such as iron and copper. In vitro studies using V79 cells have demonstrated that this compound can inhibit the growth of cancer cells. Its chelation action prevents metal ion incorporation into proteins and other molecules, thereby reducing oxidative injury.
|
| ln Vivo |
Based on the properties of its parent compound nitrilotriacetic acid, this compound may affect metal ion homeostasis in vivo through chelation, thereby influencing physiological processes dependent on metal ions. IARC notes that the free acid and trisodium salt forms are nephrotoxins in rodents, suggesting that the disodium salt may share similar toxicological characteristics.
|
| Enzyme Assay |
Cell-free assays for disodium nitrilotriacetate typically involve measuring its chelating capacity. A standard protocol includes dissolving the compound in an appropriate buffer, adding target metal ions (e.g., Fe³⁺, Cu²⁺, Ca²⁺), and measuring the formation of metal ion-chelator complexes using spectroscopic or other analytical methods. The stability of the complexes is influenced by environmental factors such as pH and temperature. This compound can interact with various enzymes, proteins, and other biomolecules, affecting their function and activity.
|
| Cell Assay |
In vitro studies using V79 cells have been conducted to evaluate the effect of disodium nitrilotriacetate on cancer cell growth. The protocol typically involves culturing V79 cells in appropriate medium, treating them with various concentrations of the compound, and assessing cell proliferation inhibition through cell counting or viability assays. Results indicate that this compound can inhibit the growth of V79 cells.
|
| Animal Protocol |
Based on toxicological studies of the parent compound NTA, in vivo experiments typically use dietary administration in rodents for long-term studies. IARC's carcinogenicity assessment of NTA cites extensive animal data showing that NTA and related salts can induce urinary tract tumors.
|
| ADME/Pharmacokinetics |
Based on the known properties of the parent compound NTA, it is presumed that this compound has low oral absorption, with the absorbed fraction being rapidly excreted unchanged in urine without significant biotransformation in vivo.
|
| Toxicity/Toxicokinetics |
Disodium nitrilotriacetate is classified by IARC as a Group 2B carcinogen (possibly carcinogenic to humans). The oral LD50 in rats is 1460 mg/kg, with toxic effects including gastrointestinal responses (nausea, vomiting). The compound targets the kidney and bladder and exhibits nephrotoxicity. GHS classification indicates it is harmful if swallowed (H302) and suspected of causing cancer (H351). Safe handling recommendations include wearing protective gloves/protective clothing/eye protection/face protection, and seeking medical advice if exposed or concerned. Chronic exposure may be associated with degenerative diseases such as Parkinson's disease or Alzheimer's disease.
|
| References |
[1]. https://pubchem.ncbi.nlm.nih.gov/compound/27301
|
| Molecular Formula |
C6H7NNA2O6
|
|---|---|
| Molecular Weight |
235.1
|
| Exact Mass |
235.007
|
| Elemental Analysis |
C, 30.65; H, 3.00; N, 5.96; Na, 19.56; O, 40.83
|
| CAS # |
15467-20-6
|
| Related CAS # |
Nitrilotriacetic acid;139-13-9;Nitrilotriacetic acid trisodium salt;5064-31-3
|
| PubChem CID |
27301
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
498.2ºC at 760mmHg
|
| Melting Point |
300 °C
|
| Flash Point |
255.1ºC
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
198
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Na+].[Na+].O([H])C(C([H])([H])N(C([H])([H])C(=O)[O-])C([H])([H])C(=O)[O-])=O
|
| InChi Key |
RHPXYIKALIRNFA-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C6H9NO6.2Na/c8-4(9)1-7(2-5(10)11)3-6(12)13;;/h1-3H2,(H,8,9)(H,10,11)(H,12,13);;/q;2*+1/p-2
|
| Chemical Name |
disodium;2-[carboxylatomethyl(carboxymethyl)amino]acetate
|
| Synonyms |
Disodium hydrogen nitrilotriacetate; 15467-20-6; Disodium nitrilotriacetate; Disodium hydrogen nitrilotriacetate; disodium nitriloacetate; Kiresuto NTB; Disodium nitrilotriacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2535 mL | 21.2675 mL | 42.5351 mL | |
| 5 mM | 0.8507 mL | 4.2535 mL | 8.5070 mL | |
| 10 mM | 0.4254 mL | 2.1268 mL | 4.2535 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
